Aligos Therapeutics, Inc. (ALGS) FinancialsALGSAligos Therapeutics, Inc.

Evaluating the bottom line, Aligos Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -6.80%, while the net margin is -5.41%. These profitability ratios, combined with a Return on Equity (ROE) of -113.59%, provide a clear picture of how effectively ALGS converts its operational activities into shareholder value.

In the context of the broader market, ALGS competes directly with industry leaders such as EYPT and BLRX. With a market capitalization of $25.30M, it holds a significant position in the sector. When comparing efficiency, ALGS's gross margin of 100.00% stands against EYPT's 100.00% and BLRX's 53.40%. Such benchmarking helps identify whether Aligos Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Aligos has shown a gross margin of 100% consistently across recent quarters, indicating strong revenue generation relative to costs. However, it has also reported significant net losses, with a recent net loss of $1.5 million in Q2 2026, down from a $15.9 million loss in the same period last year, demonstrating improved cost control.